17 results about "Single stranded oligonucleotides" patented technology

The application discloses an oligonucleotide hydrogel and a preparation method and application thereof, and comprises the following steps: sequentially adding oligonucleotide and PBS buffer into a metal salt solution to obtain a mixed solution; placing the mixed solution in a shaking table and oscillating and incubating; after incubation, centrifuging, discarding the supernatant and reserving the precipitate; resuspending the precipitate by adding deionized water, centrifuging, discarding the supernatant and washing to obtain the hydrogel; the application only needs single-stranded oligonucleotide, has no special requirements on the sequence composition and structure of the oligonucleotide, does not need special design, can be assembled with divalent and trivalent metal ions, has a simple process, is easy to operate, and can wrap biological enzymes in the hydrogel, realizes enzyme immobilization and recycling.

A system for analyzing biological components in a biological sample, wherein the system comprises a planar surface, and wherein the system is configured to perform a procedure comprising: (a) arranging a spatially connected biological sample adjacent to the planar surface, wherein: the spatially connected biological sample comprises a tissue sample, the tissue sample comprises a plurality of cells, the planar surface comprises glass, plastic, or a combination thereof, the planar surface further comprises a plurality of binding sites, the plurality of binding sites is arranged in a two-dimensional pattern on the planar surface, the planar surface comprises at least 10⁵ binding sites, each of the plurality of binding sites comprises a plurality of single-stranded oligonucleotides, and the plurality of single-stranded oligonucleotides is coupled to the planar surface.at least one subset of the plurality of single-stranded oligonucleotides comprises: (i) a binding sequence comprising a plurality of thymine bases configured to bind to poly-A sequences, (ii) a unique molecular identifier, (iii) a barcode associated with a position on the planar surface, and (iv) a sequencing primer, and each oligonucleotide of the subset of the plurality of single-stranded oligonucleotides comprises at least 50 nucleotides; (b) imaging at least a portion of the spatially linked biological sample, wherein the imaging comprises bright-field imaging, phase-contrast imaging, fluorescence imaging, or a combination thereof; (c) releasing nucleic acids from the spatially linked biological sample; and (d) capturing at least one subset of the nucleic acids on at least the subset of single-stranded oligonucleotides, thereby recovering the captured nucleic acids.the captured nucleic acids are immobilized on the flat surface.

This invention provides a preventive and / or therapeutic agent for cystic kidney disease. The preventive and / or therapeutic agent for cystic kidney disease comprises a single-stranded oligonucleotide containing a base sequence complementary to at least a portion of the base sequence of miR-21.

A single-stranded oligonucleotide having a length of 16-30 nucleotides. The composition of the single-stranded oligonucleotide enables the single-stranded oligonucleotide to inhibit the expression of target mRNA by means of an RNAi mechanism. Each nucleotide in the single-stranded oligonucleotide is independently a modified or unmodified nucleotide, wherein at least one nucleotide in the single-stranded oligonucleotide is a nucleotide X; at least one nucleotide is a fluoro-modified nucleotide; and, in the 5' to 3' direction, the 13th nucleotide of the single-stranded oligonucleotide is a substituted alkoxy-modified nucleotide, the 14th nucleotide of the single-stranded oligonucleotide is a nucleotide X, and each of the 15th nucleotide and all subsequent nucleotides of the single-stranded oligonucleotide is independently a modified nucleotide. A double-stranded oligonucleotide comprising the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate and a pharmaceutical composition.

The invention relates to a conjugate comprising or consisting of (a) at least one molecule capable of specifically binding to at least one analyte; and at least one nucleic acid nanostructure (b); wherein said nucleic acid nanostructure of (b) comprises a plurality of single-stranded oligonucleotides; and wherein at least two of said plurality of oligonucleotides each comprise a first identical nucleobase sequence.

This invention provides a method for screening highly specific nucleic acid aptamers and specific *Lactobacillus helveticus* aptamers, belonging to the field of nucleic acid aptamers. Specifically, the method for screening highly specific nucleic acid aptamers provided by this invention includes the following steps: S1: A second library is obtained after N rounds of forward screening of a first library; S2: A third library is obtained after M rounds of reverse screening of the second library; S3: The third library is obtained after X rounds of forward screening of the third library to obtain selected random single-stranded oligonucleotides, which are then subjected to PCR amplification, purification, cloning, and sequencing; S4: The sequences cloned and sequenced in step S3 are used for affinity and specificity assays to select sequences with high affinity and specificity, thereby obtaining highly specific nucleic acid aptamers. The aptamers provided by this invention have the advantages of high specificity and strong affinity, and the construction method of the aptamers provided by this invention has the advantage of short screening time.

The present disclosure provides a single-stranded oligonucleotide, wherein the single-stranded oligonucleotide has a length of 16-30 nucleotides and can inhibit the expression of APOE4 mRNA by the mechanism of RNA interference (RNAi); wherein each nucleotide in the single- stranded oligonucleotide independently of one another is a modified or unmodified nucleotide; and wherein at least one nucleotide is a nucleotide X, and at least one nucleotide is a fluoro modified nucleotide; and in a 5' to 3' direction, in the single-stranded oligonucleotide, the 13th nucleotide is a substituted alkoxy modified nucleotide; the 14th nucleotide is a nucleotide X; and each of the 15th nucleotide and all the subsequent nucleotides independently of one another is a modified nucleotide; and each nucleotide X is independently a deoxyribonucleotide or an unmodified nucleotide. The present disclosure also provides a double-stranded oligonucleotide, an oligonucleotide conjugate and a pharmaceutical composition comprising the single-stranded oligonucleotide as an antisense strand.

Provided is a single-stranded oligonucleotide capable of inhibiting the expression of PNPLA3 mRNA by means of an RNAi mechanism. The length of the single-stranded oligonucleotide is 16-30 nucleotides. Each nucleotide in the single-stranded oligonucleotide is independently a modified or unmodified nucleotide. At least one nucleotide is a nucleotide X, and at least one nucleotide is a fluoro-modified nucleotide. Moreover, in the 5' to 3' direction, the 13th nucleotide is a substituted alkoxy-modified nucleotide; the 14th nucleotide is a nucleotide X; and each of the 15th nucleotide and all subsequent nucleotides is independently a modified nucleotide. Also provided are a double-stranded oligonucleotide comprising the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate, and a pharmaceutical composition.

Provided is a single-stranded oligonucleotide which can inhibit AGT mRNA expression via the RNAi mechanism and has a length of 16-30 nucleotides, wherein each nucleotide is independently a modified or unmodified nucleotide, at least one nucleotide is a nucleotide X, and at least one nucleotide is a fluoro-modified nucleotide; furthermore, along the 5'-end-to-3'-end direction, the 13th nucleotide is a nucleotide modified with a substituted alkoxy group, the 14th nucleotide is a nucleotide X, and each of the 15th nucleotide and all the nucleotides thereafter is independently a modified nucleotide. Further provided are a double-stranded oligonucleotide containing the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate, and a pharmaceutical composition.

The present disclosure provides a single-stranded oligonucleotide, wherein the single-stranded oligonucleotide has a length of 16-30 nucleotides and can inhibit the expression of PCSK9 mRNA by the mechanism of RNA interference (RNAi); wherein each nucleotide in the single- stranded oligonucleotide independently of one another is a modified or unmodified nucleotide; and wherein in the single-stranded oligonucleotide, at least one nucleotide is a nucleotide X, and at least one nucleotide is a fluoro modified nucleotide; and in a 5' to 3' direction, the 13th nucleotide is a substituted alkoxy modified nucleotide; the 14th nucleotide is a nucleotide X; and each of the 15th nucleotide and all the subsequent nucleotides independently of one another is a modified nucleotide; and each nucleotide X is independently a deoxyribonucleotide or an unmodified nucleotide. The present disclosure also provides a double-stranded oligonucleotide, an oligonucleotide conjugate and a pharmaceutical composition comprising the single-stranded oligonucleotide as an antisense strand.

A single-stranded oligonucleotide, having a length of 16-30 nucleotides, the composition of the single-stranded oligonucleotide enabling the single-stranded oligonucleotide to inhibit the expression of NTCP mRNA by means of an RNAi mechanism. Each nucleotide in the single-stranded oligonucleotide is independently a modified or unmodified nucleotide. In the single-stranded oligonucleotide, at least one nucleotide is nucleotide X, and at least one nucleotide is a fluoro-modified nucleotide. In the direction from the 5' end to the 3' end, the 13th nucleotide of the single-stranded oligonucleotide is a substituted alkoxy-modified nucleotide, the 14th nucleotide of the single-stranded oligonucleotide is nucleotide X, and the 15th nucleotide and all the following nucleotides of the single-stranded oligonucleotide are each independently a modified nucleotide. Also provided are a double-stranded oligonucleotide including the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate, and a pharmaceutical composition.

A single-stranded oligonucleotide. Each nucleotide in the single-stranded oligonucleotide is independently a modified or unmodified nucleotide, wherein the single-stranded oligonucleotide has a length and composition that enable the single-stranded oligonucleotide to inhibit the expression of PSD3 mRNA in animals by means of an RNAi mechanism. Disclosed are a double-stranded oligonucleotide comprising the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate, and a pharmaceutical composition.

One aspect of the present invention relates to a single-stranded oligonucleotide having a sequence represented by formula (II) or (III): (5'-Z 11 -3')-L-Q S -(5'-Z 12 -3')(II), (3'-Z 11 -5')-L-Q S -(3'-Z 12 -5')(III). In formula (II) or (III), Z 11 is a first oligonucleotide comprising 15 to 100 optionally modified nucleotides that is substantially complementary to the target gene; Z 12 is a second oligonucleotide comprising 10 to 100 optionally modified nucleotides that is substantially complementary to Z 11 ; Z 11 and Z 12 can form an intrastrand double-stranded region containing 7 or more consecutive base pairs; Q S represents 0 to 12 optionally modified nucleotides; L is an arbitrary linking group; at least one nucleotide of formula (II) is a modified nucleotide; at least one nucleotide of formula (III) is a modified nucleotide; at least one nucleotide at the 3'-end of Z 11 in formula (II), or at least one nucleotide at the 5'-end of Z 11 in formula (III), in either case together with L and Q S forms a loop region connecting Z 11 and Z 12 .

A system for analyzing biological components in a biological sample, wherein the system comprises a planar surface, and wherein the system is configured to perform a procedure comprising: (a) arranging a spatially connected biological sample adjacent to the planar surface, wherein: the spatially connected biological sample comprises a tissue sample, the tissue sample comprises a plurality of cells, the planar surface comprises glass, plastic, or a combination thereof, the planar surface further comprises a plurality of binding sites, the plurality of binding sites is arranged in a two-dimensional pattern on the planar surface, one of the numerous binding sites has a dimension of about 1 micrometer to about 20 micrometers, each of the numerous binding sites comprises a plurality of single-stranded oligonucleotides, and the plurality of single-stranded oligonucleotides is coupled to the planar surface.wherein at least one subset of the plurality of single-stranded oligonucleotides comprises: (i) a binding sequence comprising a plurality of thymine bases configured to bind to poly-A sequences, (ii) a unique molecular identifier, (iii) a barcode associated with a position on the planar surface, and (iv) a sequencing primer, and each oligonucleotide of the subset of the plurality of single-stranded oligonucleotides comprises at least 50 nucleotides; (b) imaging at least a portion of the spatially linked biological sample, wherein the imaging comprises bright-field imaging, phase-contrast imaging, fluorescence imaging, or a combination thereof; (c) releasing nucleic acids from the spatially linked biological sample; and (d) capturing at least one subset of the nucleic acids on at least the subset of single-stranded oligonucleotides, thereby recovering the captured nucleic acids.the captured nucleic acids are immobilized on the flat surface.

The present disclosure provides a single-stranded oligonucleotide with the length of 16-30 nucleotides, and composition of the single-stranded oligonucleotide enables the single-stranded oligonucleotide to inhibit expression of a Lp(a) mRNA through a RNAi mechanism; each nucleotide in the single-strand oligonucleotide is a modified or unmodified nucleotide, in the single-strand oligonucleotide, at least one nucleotide being a nucleotide X and at least one nucleotide being a fluoro modified nucleotide; and in a 5' to 3' direction, at least 1 nucleotide X is located downstream from the 8th nucleotide in the single-stranded oligonucleotide and separated from the 8th nucleotide by 4-7 nucleotides. The present disclosure further provides a double-stranded oligonucleotide comprising the single-stranded oligonucleotide as an anti-sense strand, an oligonucleotide conjugate and a pharmaceutical composition.